AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01344252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: We will made anesthesia with topical lidocaine and compared with subtenon anesthesia
Study NCT01344252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: We will made anesthesia with topical lidocaine and compared with subtenon anesthesia
Study NCT03031548 — intervention group
Intervention type: DEVICE
Intervention: Point-of-care ultrasound exam
Description: No intervention
Study NCT03031548 — intervention group
Intervention type: RADIATION
Intervention: Reposition ETT
Description: ETT will be repositioned based on CXR by fluoroscopy
Study NCT02677220 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CI532 cochlear implant
Study NCT01705548 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiosurgery
Description: Radiation Therapy will consist of partial brain irradiation delivered to the metastatic brain tumor or resection cavity, delivered in 5 treatments with 2-3 treatments delivered per week.
Study NCT00276549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: IV over 30 minutes on days 1 and 8 followed by docetaxel IV over 60 minutes on day 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Study NCT01848639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to spironolactone. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
Study NCT01848639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to placebo. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
Study NCT04613505 — intervention group
Intervention type: BEHAVIORAL
Intervention: Semi-structured interview
Description: Participants will be asked a set of questions as applicable to each phase. Researchers will be able to ask additional questions as they arise within each interview.
Study NCT04613505 — intervention group
Intervention type: BEHAVIORAL
Intervention: Same day consent questionnaire
Description: A questionnaire (yet to be developed) will be administered to participants.
Study NCT02471911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-330
Description: KPT-330 administered orally on days -5 and -3 prior to starting chemotherapy. Once chemotherapy starts, KPT-330 will be administered on days 1, 3, and 5 of each cycle. Dose levels will range from 20 mg to 100mg with a standard 3+3 escalation schema.
Study NCT02471911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV Rituximab 375 mg/m2 on D1
Study NCT02471911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: IV Etoposide 100 mg/m2 on D1-3
Study NCT02471911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Carboplatin AUC 5 on D2
Study NCT02471911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: IV Ifosfamide 5 g/m2 on D2
Study NCT02471911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg qd on Days -5 and -3. 20 mg qd on Days 1-5
Study NCT03034408 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nalmefene
Study NCT03034408 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Baclofen
Study NCT03034408 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Oral Capsule
Study NCT03728140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-spent Culture Medium
Description: Replace embryo transfer solution with Self-spent culture medium in IVF-ET.
Study NCT04367441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 608
Description: recombinant humanized anti-IL17A monoclonal antibody injection
Study NCT04367441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: auxiliary material of 608 include histidine, histidine hydrochloride, sucrose and polysorbate 80
Study NCT00355849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Insulin Inhalation Powder
Description: patient specific dose, inhaled, before meals, 52 weeks
Study NCT00355849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: patient specific dose, injectable, before meals, 52 weeks
Study NCT00233818 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sirolimus-coated Bx VELOCITY Stent
Study NCT04545398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food. Beef, Pasture-raised
Description: Pasture-raised beef
Study NCT04545398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food. Beef, Grain-fed
Description: Grain-fed beef
Study NCT04545398 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Food. Meat alternative
Description: Meat alternative
Study NCT02072148 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: PET scan or CT scan q 4 months for 5 years
Study NCT02072148 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Postoperative XRT 5000 cGy
Study NCT02072148 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent Chemoradiation
Description: CCRT with cisplatin 40mg/m2/week IV over approximately 30 minutes, mixed in 250ml normal saline Weekly on Monday or Tuesday any time, or Wednesday prior to radiation~Postoperative XRT 5000 cGy
Study NCT02072148 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent Chemoradiation
Description: CCRT with cisplatin 40mg/m2/week IV over approximately 30 minutes, mixed in 250ml normal saline Weekly on Monday or Tuesday any time, or Wednesday prior to radiation~Postoperative XRT 5600 cGy
Study NCT04403711 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: local anesthetic and dexmedetomidine
Description: in patients allocated to the dexmedetomidine group, ultrasound-guided transversus abdominis plane block will be performed with the combination of local anesthetic and dexmedetomidine
Study NCT04403711 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: local anesthetic and placebo
Description: in patients allocated to the dexmedetomidine group, ultrasound-guided transversus abdominis plane block will be performed with the combination of local anesthetic and normal saline
Study NCT03330912 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neutral seat height
Description: Seat height set relative to participant's leg length with neutral set at the measured lower leg length
Study NCT03330912 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Very low seat height
Description: Seat height set relative to participant's leg length, 2 below the measured lower leg length
Study NCT03330912 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low seat height
Description: Seat height set relative to participant's leg length, 1 below the measured lower leg length
Study NCT03330912 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Very high seat height
Description: Seat height set relative to participant's leg length, 2 above the measured lower leg length
Study NCT03330912 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High seat height
Description: Seat height set relative to participant's leg length, 1 above the measured lower leg length
Study NCT04545398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food, Lamb
Description: Lamb
Study NCT03729076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crystalloid
Description: Patients will receive the rapid co-loading with plasma solution A (PSA) 10ml/kg, from the initiation of spinal anesthesia, within 10 minutes.
Study NCT03729076 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colloid
Description: Patients will receive the rapid co-loading with 6% volulyte (HES in acetated electrolyte) 10ml/kg, from the initiation of spinal anesthesia, within 10 minutes.
Study NCT02960061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Description: Eligible patients receive 4 cycles of mDOF(docetaxel 50 mg/ m2 day 1 + oxaliplatin 85 mg/ m2 day 2 + fluorouracil 400 mg/ m2 bolus iv followed by 600 mg/ m2 22 hours chronic infusion, day 2/3 + leucovorin 200 mg/ m2, day2/3; repeated every 14 days ).
Study NCT03215043 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The selected individuals will be randomly distributed in 4 groups through random number generator program. Group A (n = 20) will receive a dose of 140 mg / d eriocitrin; Group B (n = 20) eriocitrin 280 mg / d; The C group (n = 20) 560 mg / d eriocitrin; And group D (n = 20) will receive the placebo with corn starch excipient. All doses will be packaged in Manipulation Pharmacy, and should be of the same type, color and size. Individuals will be instructed to regularly ingest a pre-dinner capsule for 12 weeks.
Study NCT02960061 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Neoadjuvant chemotherapy
Description: Eligible patients receive 4 cycles of mDOF(docetaxel 50 mg/ m2 day 1 + oxaliplatin 85 mg/ m2 day 2 + fluorouracil 400 mg/ m2 bolus iv followed by 600 mg/ m2 22 hours chronic infusion, day 2/3 + leucovorin 200 mg/ m2, day2/3; repeated every 14 days ).
Study NCT03998917 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Discrimination of neuromuscular alterations protocol
Description: Patients will perform a hand grip fatigability test with their dominant hand, followed by a Timed Up and Go Test (TUG-Test), a Five-repetition sit-to-stand-test (5STS-Test) and a10 meters gait speed test.
Study NCT04201977 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Foam Roller Recovery
Description: Myofascial self-release will be developed through the foam roller (FR), where participants will use a custom-made foam roller constructed from a hollow polyvinyl chloride tube that will have an outside diameter of 10cm and a thickness of 0.5cm and will be surrounded by neoprene foam with a thickness of 1cm. Each volunteer will be shown the technique for the 5 muscle groups involved and the technique used for each muscle group. FR will consist of 45s of rolling for each muscle in the left lower extremity, 15s of rest, 45s in the lower right extremity. They will be instructed to begin with the practice on the most distal portion of the muscle. They will be instructed to place as much tolerable body mass on the FR at all times and to roll their body mass back and forth along the roller as smoothly as possible at a rate of 50 beats per minute (ie , 1 rolling motion for 1 to 2s). The total technique time is estimated at 10 to 15min (PEARCEY et al., 2015).
Study NCT04201977 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active recovery
Description: Active recovery for 20 minutes (MIKA et al., 2016) will consist of pedaling on a stationary bike at a speed of 50 to 60 rpm. The load (49 ± 9 W) will be adjusted individually so that the heart rate is close to 100 bpm (about 50% of the theoretical maximum heart rate). This effort intensity is similar to that used in the literature (CRISAFULLI et al., 2003; FAIRCHILD et al., 2003; VANDERTHOMMED; MAKROF; DEMOULIN, 2010)
Study NCT04201977 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immersion in cold water
Description: Immersion in cold water will consist of the individual sitting in a plastic pool with water at the water level of the umbilical scar. Water temperature is between 11 and 15ºC, for a period between 10 and 15 minutes immediately after the exercise protocol (MACHADO et al., 2016b; MCDERMOTT et al., 2009). Water temperature will be controlled by adding or removing ice. This method has been applied by studies conducted by our research group (MISSAU; SIGNORI, 2017).
Study NCT04201977 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive recovery
Description: Volunteers will be seated for 20 min after the resistance exercise session (TEIXEIRA et al., 2014a, 2014b).
Study NCT02431130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low-fidelity instructor driven simulation training
Study NCT02750267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diabetes Assistant (DiAs) with Closed-Loop
Description: All subjects will use DiAs Medical Platform, a study insulin pump and continuous glucose monitor (CGM) in closed-loop mode during a Research House/Hotel admission that will last up to 72 hours.
Study NCT04649619 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: GASTRIC BYPASS MODIFIED IN ROUX-EN-Y AS A THERAPEUTIC OPTION IN PATIENTS WITH INDICATION OF BARIATRIC AND / OR METABOLIC SURGERY
Description: Roux-en-Y gastric bypass:~Stapling and reduction of the gastric chamber of approximately 18 cm, followed by anastomosis with a deviated bowel, and another bowel anastomosis with a bowel in a lower portion, for deviation of biliopancreatic secretions. Maintenance of a gastro-gastric communication of approximately 1 cm between the functional gastric pouch and the excluded stomach for endoscopic access.
Study NCT04090268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sport Therapy
Description: Children and adolescent with malignant hemopathies will attend a 3 days/weekly combined training
Study NCT02726529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brighter Bites
Study NCT02726529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CATCH
Description: The comparison schools received training in implementing the Coordinated Approach to Child Health (CATCH) school-based health promotion program
Study NCT02726529 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CATCH
Description: The comparison schools received training in implementing the Coordinated Approach to Child Health (CATCH) school-based health promotion program
Study NCT01379807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab + docetaxel + cisplatino
Description: Panitumumab, docetaxel and cisplatin combination treatment will be administered for 6 months or until disease progression (PD) according to investigator's criteria unacceptable toxicity or consent withdrawal.
Study NCT02960061 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D2 radical resection
Description: Laparotomy or laparoscopic surgery are chosen according to the preference of the surgeon. Either cases, a throughout peritoneal cavity exploration is required to comfirmed the tumor resectability and peritoneal metastasis. A curative D2 resection is performed if achievable.
Study NCT02960061 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: D2 radical resection
Description: Laparotomy or laparoscopic surgery are chosen according to the preference of the surgeon. Either cases, a throughout peritoneal cavity exploration is required to comfirmed the tumor resectability and peritoneal metastasis. A curative D2 resection is performed if achievable.
Study NCT02960061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal perfusion chemotherapy
Description: Two cycle of hyperthermic intraperitoneal perfusion chemotherapy is administered to patients who have received neoadjuvant chemotherapy and D2 resection, dosage and the relative parameter setting is described above.
Study NCT02960061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Description: Adjuvant chemotherapy using SOX or XELOX regimen will be administered as routine within 4-6 weeks.
Study NCT02960061 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Adjuvant chemotherapy
Description: Adjuvant chemotherapy using SOX or XELOX regimen will be administered as routine within 4-6 weeks.
Study NCT02927977 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises and manual therapy. Participants will receive 4-6 treatments during 4 weeks.
Study NCT02927977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dry needling
Description: Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises, manual therapy and dry needling in neck muscles. Participants will receive 4-6 treatments during 4 weeks.
Study NCT01335997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ER niacin/laropiprant (ERN/LRPT)
Description: ER niacin 1 g/laropiprant 20 mg oral tablet taken once daily
Study NCT01335997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ER niacin/laropiprant (ERN/LRPT)
Description: ER niacin 1 g/laropiprant 20 mg oral tablet taken once daily
Study NCT01335997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM)
Description: ER niacin 1 g/laropiprant 20 mg/simvastatin 10 mg oral tablet taken once daily
Study NCT01335997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM)
Description: ER niacin 1 g/laropiprant 20 mg/simvastatin 10 mg oral tablet taken once daily
Study NCT01335997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin (SIM)
Description: Simvastatin 10 mg oral tablet taken once daily
Study NCT01335997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin (SIM)
Description: Simvastatin 10 mg oral tablet taken once daily
Study NCT01335997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Run-In
Description: Placebo matches both ER niacin 1 g/laropiprant 20 mg oral tablet and ER niacin 1 g/laropiprant 20 mg/simvastatin 10 mg oral tablet; placebo is taken once daily
Study NCT01335997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Run-In
Description: Placebo matches both ER niacin 1 g/laropiprant 20 mg oral tablet and ER niacin 1 g/laropiprant 20 mg/simvastatin 10 mg oral tablet; placebo is taken once daily
Study NCT01335997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SIM-matching placebo
Description: Placebo for simvastatin 10 mg oral tablet taken once daily
Study NCT01335997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM-matching placebo
Description: Placebo for simvastatin 10 mg oral tablet taken once daily
Study NCT00794391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: Motivational interviewing is a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence (Miller \& Rollnick. 1993). This 45 minutes individual motivational intervention focuses on risky injection practices.
Study NCT00794391 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational intervention
Description: The educational intervention is a 45 minutes individual intervention based on a document written by the Québec ministry of health (Québec, Canada). The aim is to inform participants about safe injection practices and to show them how to use sterile injection equipment.
Study NCT00006472 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: carboplatin
Description: Carboplatin AUC 6 days 1 and 22
Study NCT00006472 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: fluorouracil
Description: 5FU 225mg/m2 continuous infusion on days 1-42 during radiation
Study NCT00006472 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: paclitaxel
Description: taxol
Study NCT00006472 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: conventional surgery
Study NCT00006472 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy
Description: The initial fields should be treated AP:PA when possible to a dose of 4500 cGy in 180 cGy fractions
Study NCT03362918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: The exercise prescription is as follows:~Type: High-Intensity Interval Training on a treadmill, elliptical trainer or cycle ergometer.~Intensity: 30 seconds of high-intensity alternating with 90 seconds of low intensity for a total of 10 cycles~* High intensity for most individuals will occur at approximately 90% of maximum heart rate. Using the rating of perceived exertion scale, participants should be exercising at a 9/10, which is very difficult to maintain the intensity and results in only being able to speak a few words at a time.~* Low intensity is defined as light activity and rated as 2-3/10 on the rating of perceived exertion scale. Participants should be able to carry on a conversation and maintain the pace for hours.~Duration: 30 minutes Frequency: 3 times per week
Study NCT03362918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous Aerobic Exercise Training
Description: The exercise prescription for the continuous aerobic exercise group is as follows:~Type: Aerobic exercise including walking, running, cycling or using the elliptical trainer.~Intensity: Moderate intensity, defined as 50-60% of the participant's maximum heart rate. On the rating of perceived exertion scale, this corresponds with a 4-6/10, which allows participants to hold a conversation while breathing heavily.~Duration: 50 minutes Frequency: 3 times per week
Study NCT01797835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHAT brief MI intervention
Description: CHAT is one 15-20 minute session delivered in a single PC visit and utilizes motivational interviewing with youth to target alcohol and drug use in primary care.